CTEC Global X CleanTech ETF

Cholestech Testing System Enhances Life Line Screening's Community-based Preventive Health Screenings for Stroke, Vascular Disease and Osteoporosis HAYWARD, Calif., Nov. 8 /PRNewswire-FirstCall/ -- Cholestech Corporation (NASDAQ:CTEC), a leading provider of point-of-care health management solutions for chronic disease, and Life Line Screening, America's leading provider of mobile preventive health screenings, have teamed up to bring cholesterol, glucose and c-reactive protein testing directly to consumers across the country. With 85 vans across the U.S. and 1.4 million participants per year, Life Line Screening, the leader in the emerging trend of consumer- accessible screenings for stroke, vascular disease and osteoporosis has selected the market-leading Cholestech LDX(R) point-of-care testing system to screen Americans for risk factors associated with stroke, heart disease, diabetes and inflammatory disorders. (Photo: http://www.newscom.com/cgi-bin/prnh/20060504/NYTH042 ) The LDX testing system will become part of Life Line Screening's current offering of affordable, high-quality mobile preventive health services, which include non-invasive ultrasound screenings for stroke, abdominal aortic aneurysm, peripheral arterial disease, and osteoporosis. In collaboration with Cholestech, Life Line Screening -- whose mission is to help people preserve their healthy, independent lifestyles -- can now provide its participants laboratory-accurate results of their complete lipid panel, including total cholesterol, LDL, HDL and triglycerides; blood glucose; and high sensitivity C-reactive protein. "Convenient blood testing for risks associated with diabetes, inflammatory disorders, stroke, and coronary heart disease is an important, natural adjunct to Life Line Screening's current preventive health screenings," said Andrew Manganaro, M.D., Medical Director for Life Line Screening. "We selected the Cholestech LDX system after a thorough search for a point-of-care testing system that offers a full scope of screening tests for immediate risk assessment, is easy to use, and provides rapid and accurate results. "Cholestech emerged as the clear leader, particularly since the Cholestech LDX system is certified by the Cholesterol Reference Method Laboratory Network (CRMLN) for accuracy and reproducibility, and can be conducted in conjunction with the other Life Line Screening tests," Dr. Manganaro said. "With its extensive community reach throughout the U.S., Life Line Screening can now bring the convenience, accuracy and benefits of Cholestech point-of-care testing to consumers directly in their own neighborhoods," said Warren E. Pinckert II, president and CEO of Cholestech. "This immediate access to health risk assessment for heart disease, stroke, inflammatory disorders and diabetes from a simple and rapid health screening test will help save lives and reduce health care costs." Life Line Screening will phase in the new preventive health screening services at local community and senior centers and other venues in 27 states before the end of the year. The exclusive three year agreement between Cholestech and Life Line Screening began in mid 2006 and in 2007; all Life Line Screening mobile teams nationwide are expected to offer the Cholestech screening tests. About Cholestech Cholestech is committed to enabling people to lead longer, healthier and more active lives. Cholestech provides easy to use, accessible diagnostic tools and information to health care practitioners in over 35 countries around the world. Cholestech offers efficient and economic diagnostic testing for cholesterol and related lipids, blood glucose and glycemic control, and liver enzymes at the point of care. Health care providers can use the CLIA-waived Cholestech LDX(R) System and the GDX(TM) System(1), which is approved for prescription home use and for use in moderate complexity labs, to initiate and monitor the progress of patient therapy. By providing effective disease management solutions, Cholestech's goal is to be a leading provider of diagnostic tools and information for immediate risk assessment and therapeutic monitoring of heart disease and diabetes. Cholestech LDX(R) is a registered trademark and Cholestech GDX(TM) is a trademark of Cholestech Corporation. All other trademarks mentioned in this document are the property of their respective owners. For more information about Cholestech and its products visit us on the Web at http://www.cholestech.com/. About Life Line Screening Life Line Screening empowers Americans age 50 and older and those at risk to protect their independence, health and vitality by offering non-invasive, inexpensive, painless and easy-to-obtain preventive health ultrasound screening tests that identify risk of stroke, vascular diseases and osteoporosis. Established in 1993, the Cleveland, Ohio-based company is the nation's leading provider of mobile preventive health screenings with more than 80 highly trained ultrasound teams conveniently bringing preventive health screenings to every corner of America. Life Line Screening also partners with more than 350 hospitals nationwide. The privately held company has screened more than 4.5 million Americans and discovered significant vascular disease and osteoporosis risk in hundreds of thousands of asymptomatic people. For more information about Life Line Screening call 1-800-697-9721 or visit http://www.lifelinescreening.com/ (1) GDX is 510(k) cleared for prescription home use and, accordingly, is CLIA waived. CONTACT: Heather Battaglia 516-536-6811 http://www.newscom.com/cgi-bin/prnh/20060504/NYTH042 http://photoarchive.ap.org/ DATASOURCE: Cholestech Corporation CONTACT: Heather Battaglia, +1-516-536-6811 or , for Cholestech Corporation Web site: http://www.cholestech.com/

Copyright